| Project/Area Number |
19591946
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Osaka Medical College |
|---|
Principal Investigator |
TERAI Yoshito Osaka Medical College, 医学部, 講師 (90278531)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OHMICHI Masahide 大阪医科大学, 医学部, 教授 (10283764)
KANEMURA Masanori 大阪医科大学, 医学部, 講師 (40298782)
TANABE Akiko 大阪医科大学, 医学部, 助教 (70454543)
SASAKI Hiroshi 大阪医科大学, 医学部, 助教 (80432491)
竹原 幹雄 大阪医科大学, 医学部, 助教 (40298766)
|
|---|
| Project Period (FY) |
2007 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2007: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 耐性卵巣癌 / 分子標的治療 / イレッサ / 婦人科腫瘍学 / 卵巣癌 / 抗血管新生治療 / 維持療法 |
|---|
| Research Abstract |
Combination therapy with bevacizumab and cisplatin for 3 weeks was associated with complete disappearance of all macroscopic evidence of disease in the nude mouse xenograft model. Twenty-nine EGFR mutations were detected in 24 of 102 patients with ovarian cancer. EGFR gene mutation status was not significantly related to survaival time. Topotecan inhibits Akt kinase activity and VEGF transcriptional activation after Cisplatin treatment in platinum-resistant ovarian cancers. These results provide a rationale for using Topotecan in clinical regimens aimed at molecular targeting agents in platinum-resistant ovarian cancers.
|
